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Background: Increasing evidences link T helper 17 (Th17) cells with multiple sclerosis (MS). In this context,
interleukin-22 (IL-22), a Th17-linked cytokine, has been implicated in blood brain barrier breakdown and lymphocyte
infiltration. Furthermore, polymorphism between MS patients and controls has been recently described in the gene
coding for IL-22 binding protein (IL-22BP). Here, we aimed to better characterize IL-22 in the context of MS.
Methods: IL-22 and IL-22BP expressions were assessed by ELISA and qPCR in the following compartments of MS
patients and control subjects: (1) the serum, (2) the cerebrospinal fluid, and (3) immune cells of peripheral blood.
Identification of the IL-22 receptor subunit, IL-22R1, was performed by immunohistochemistry and immunofluorescence
in human brain tissues and human primary astrocytes. The role of IL-22 on human primary astrocytes was evaluated
using 7-AAD and annexin V, markers of cell viability and apoptosis, respectively.
Results: In a cohort of 141 MS patients and healthy control (HC) subjects, we found that serum levels of IL-22 were
significantly higher in relapsing MS patients than in HC but also remitting and progressive MS patients. Monocytes and
monocyte-derived dendritic cells contained an enhanced expression of mRNA coding for IL-22BP as compared to HC.
Using immunohistochemistry and confocal microscopy, we found that IL-22 and its receptor were detected on
astrocytes of brain tissues from both control subjects and MS patients, although in the latter, the expression was higher
around blood vessels and in MS plaques.
Cytometry-based functional assays revealed that addition of IL-22 improved the survival of human primary astrocytes.
Furthermore, tumor necrosis factor α-treated astrocytes had a better long-term survival capacity upon IL-22
co-treatment. This protective effect of IL-22 seemed to be conferred, at least partially, by a decreased apoptosis.
Conclusions: We show that (1) there is a dysregulation in the expression of IL-22 and its antagonist, IL-22BP, in
MS patients, (2) IL-22 targets specifically astrocytes in the human brain, and (3) this cytokine confers an increased
survival of the latter cells.
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Multiple sclerosis (MS) occurs in genetically predisposed
young adults with probable environmental triggers [1].
Infiltrating auto-reactive immune cells, in synergy with
resident glial cells, will cause neuroinflammation and
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creativecommons.org/publicdomain/zero/1.0/axonal loss, and finally irreversible damage to the central
nervous system (CNS) [2]. Pro-inflammatory T helper
17 (Th17) cells have been associated with MS [3–9], but
the function of Th17 cells in the pathogenesis of MS is
still a matter of debate [10–12].
Interleukin-22 (IL-22), a Th17-linked cytokine, is associ-
ated with autoimmune diseases such as inflammatory
bowel diseases and psoriasis [13]. Depending on the tar-
geted tissue and the cytokine milieu in which it is released,
IL-22 can contribute to inflammation, chemotaxis, and
host defense but also to cell survival, tissue protection,
wound healing, and epithelial cell proliferation [14–20].rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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human diseases [21]. Together with IL-17, IL-22 seems
to compromise the blood brain barrier integrity, enab-
ling lymphocyte ingress into the CNS, which raises the
possibility that this cytokine may contribute to MS
severity [22]. The melanoma cell adhesion molecule
(MCAM) has been associated with infiltration of T cells
into CNS lesions together with an increased expression
of IL-17 and IL-22 in MCAM+ T cells as compared to
MCAM− T cells [23, 24]. Somewhat contrasting with the
previous findings, some data suggest that IL-22 may not
necessarily be pro-inflammatory: in Theiler’s virus-
induced demyelination in mice, epitope-specific CD8+ T
cells causing minimal cytotoxicity in the CNS expressed a
higher level of IL-22 mRNA than highly cytotoxic CD8+ T
cells [25]. IL-22 may even be useful for tissue-protective
therapy [26]. Further suggesting that IL-22 may be in-
volved in MS, genetic studies showed that the gene coding
for IL-22 binding protein (IL-22BP, also called IL-22RA2),
an antagonist of IL-22 [27–30], harbored different single
nucleotide polymorphism in MS patients as compared to
control subjects [31–34]. Interestingly, this secreted IL-
22 inhibitory receptor exacerbates experimental auto-
immune encephalomyelitis (EAE) disease course [31, 35],
raising the question whether IL-22 itself may have an anti-
inflammatory function in EAE.
These data suggest that IL-22 may be involved in the
immunopathogenesis of MS. However, this cytokine has
been barely studied in MS patients. Here, we investi-
gated whether IL-22 and IL-22BP are dysregulated in
MS. We further aimed at identifying its target cells in
human brain tissues, in particular in MS patients, and
determining its functional effect in the CNS.
Methods
Study subjects
For the studies pertaining to the determination of IL-22
and IL-22BP levels in the blood, 141 MS patients and
healthy control (HC) subjects were enrolled and divided
into subgroups according to the disease type (Table 1).
The diagnosis of MS followed the revised McDonald cri-
teria [36]. The category of clinically active multiple scler-
osis patients comprised relapsing remitting (RR)-MS or
clinically isolated syndrome (CIS), who had a relapse
that started less than 2 months prior to our assays. The
category of clinically inactive multiple sclerosis patients
included RR-MS and CIS patients who were in remis-
sion, as defined by an interval of more than 3 months
after the last relapse. The category of progressive MS pa-
tient group contained patients with secondary progres-
sive (SP)-MS or primary progressive (PP)-MS. Clinically
inactive, SP- and PP-MS patients were not under any
treatment within the 3 months prior to the blood draw.
Among the 26 clinically active MS patients, four wereon interferon-β, one on natalizumab, and one on fingoli-
mod treatments. None of the MS patients had received
corticosteroids in the previous 3 months. All enrolled
patients and healthy control subjects signed an informed
consent form, according to our institution review board.
For immunohistochemistry studies, brain biopsies
from 11 non-MS patients were obtained from neurosur-
gical resections performed in the service of neurosurgery
at the CHUV in Lausanne, hereafter referred to as the
“Lausanne cohort” (Table 2). Tissues from five MS pa-
tients with their seven control counterparts obtained
after postmortem autopsies were processed in Basel and
named “Basel cohort” (Table 2). All human brain tissues
were collected in accordance with local ethical commit-
tee from the University Hospitals of Lausanne and Basel
and the UK MS Tissue Bank.
Human brain tissues
Lausanne cohort
In Lausanne, biopsied brain tissues were obtained only
from non-MS study subjects. Just after biopsy, these
ex vivo brain tissues, encompassing either white matter
(WM), gray matter (GM), or both, were frozen and stored
at −80 °C until they were cut to obtain 12-μm cryosections
for immunofluorescence experiments. Hereafter, biopsied
brain tissues from Lausanne cohort are named L-C1 to
L-C11 (Lausanne-Control #1–11; Table 2).
Basel cohort
In Basel, brain tissues were obtained from postmortem
autopsies supplied by the UK Multiple Sclerosis Tissue
Bank at the Imperial College (UK Multicentre Research
Ethics Committee, MREC/02/2/39), funded by the Mul-
tiple Sclerosis Society of Great Britain and Northern
Ireland (registered charity 207,495). In addition to the
brains of MS patients, there were also brain samples, in-
cluding cortex and subcortical WM, from non-MS con-
trol patients (Table 2). Postmortem autopsy tissues were
directly frozen and stored at −80 °C before use. Cryostat
tissue sections (12 μm) from MS and control subject
were mounted on Superfrost plus slides (Merck), dried
for 30 min, and fixed with 4 % paraformaldehyde in
phosphate-buffered saline (PBS) for 10 min at room
temperature (RT). Slides were washed in PBS before
staining. Brain tissues from Basel cohort are listed B-C1
to B-C7 and B-MS1 to B-MS5, referring to Basel control
subjects and MS patients, respectively (Table 2).
Primary human astrocytes
Human primary astrocytes (HA) derived from brain
cerebral cortex were purchased from ScienCell Research
Laboratory and were cultured according to the pro-
vider’s instructions. Briefly, HA were grown and cultured
at 37 °C with 5 % CO2, in astrocyte medium (AM),
Table 1 Study subjects for the assessment of IL-22 and IL-22BP in the blood
Category N = 141 Male/female
ratio






Clinically active MS patients 26 7/19 31.5 ± 10.0 2.00 ± 1.00 0.63 ± 7.19 0.46 ± 0.82
Clinically inactive MS patients 35 10/25 39.5 ± 11.5 1.50 ± 0.63 7.00 ± 9.25 16.87 ± 34.43
Progressive MS patients 35 12/23 52.0 ± 15.0 4.50 ± 2.50 17.0 ± 12.0 –
Healthy control subjects 45 21/24 34.0 ± 28.5 – – –
MS multiple sclerosis, EDSS expanded disability status scale
aMedian ± interquartile range
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astrocyte nutritive supplement with 1 % penicillin/strepto-
mycin (referred as “complete astrocyte medium”). For im-
munofluorescence, cells were fixed for 15 min with 4 %
paraformaldehyde and stored in phosphate-buffered saline
(PBS) at 4 °C. For flow cytometry, cells were resuspended
with trypsin (BioConcept) and first labeled with LIVE/
DEAD fixable violet dead cell stain (Life Technologies).
Then, HA were stained with cytofix/cytoperm (BD Biosci-
ences) with mouse anti-IL-22R1 (clone 305405, R&D Sys-
tems)/mouse IgG1 isotype control (clone 11711, R&D
Systems) or rabbit anti-IL-10R2 (sc-69580, Santa Cruz
Biotechnology)/rabbit IgG isotype control (AB-105-C,
R&D Systems) primary antibodies and followed by donkey
anti-mouse IgG AF546 and goat anti-rabbit IgG AF488
(Invitrogen) secondary antibodies. Alternatively, cell sus-
pension was directly used for staining as described in
“Proliferation and cell death/apoptosis assays” section.
Cells were processed with an LSRII flow cytometer (BD
Biosciences) and were analyzed with FlowJo software (ver-
sion 9.1.11, Treestar).PBMC isolation and cell sorting
Peripheral blood mononuclear cells (PBMC) were freshly
isolated by Ficoll (GE Healthcare Biosciences) as de-
scribed previously [37]. PBMC subpopulations were
sorted with anti-CD4, anti-CD8, anti-CD14, anti-CD19,
and anti-CD56 MicroBeads (Miltenyi Biotec) with an
autoMACS Pro Separator (Miltenyi Biotec) according to
manufacturer’s instructions. The purity of sorted cells
was checked by flow cytometry with the following anti-
bodies: anti-CD4 APC-H7 (clone SK3, BD Biosciences),
anti-CD4 ECD (clone SFCI12T4D11, Beckman Coulter),
anti-CD8 FITC (clone RPA-T8, BD Biosciences), anti-
CD11c APC (clone B-ly6, BD Biosciences), anti-CD14
PB (clone M5E2, BD Biosciences), anti-CD19 PE (clone
HIB19, eBioscience), and anti-CD56 PE-Cy7 (clone
NCAM16.2, BD Biosciences) on a LSRII flow cytometer
(BD Biosciences). We did not pursue the proposed
experiments if the purity of sorted cells was less than 90
%. Analyses were performed using FlowJo software
(Treestar).Generation of in vitro monocyte-derived dendritic cells
Sorted CD14+ cells were incubated for 6 days at 1*10e6
cells per ml in Roswell Park Memorial Institute (RPMI;
Gibco, Life Technologies) supplemented with 10 % FCS
(heat inactivated, PAA Laboratories), 50 ng/ml premium
grade recombinant granulocyte macrophages colony-
stimulating factor (GM-CSF) and 20 ng/ml premium
grade recombinant IL-4 (Miltenyi Biotec) to obtain dif-
ferentiated monocyte-derived DCs (moDCs). Cell differ-
entiation quality was checked by flow cytometry with
the following antibodies: anti-CD11c APC (clone B-ly6,
BD Biosciences) and anti-CD14 PB (clone M5E2, BD
Biosciences). Proper differentiation was considered as
completed when at least 80 % of the harvested cells were
CD11c+CD14−. For mRNA analysis, moDCs were lysed
with RLT Plus buffer (Qiagen) and kept at −20 °C until
further extraction.Leukocyte stimulation
Whole PBMC were left untreated or stimulated with 100
ng/ml staphylococcal enterotoxin B (SEB, Sigma) at
2*10e6 cells per ml for 18 h at 37 °C. Supernatants were
harvested and stored at −80 °C until use. CD4+, CD8+,
CD14+, CD19+, CD56+ sorted cells, and moDCs were
either left untreated or stimulated at 2*10e6 cells per ml
with 100 ng/ml SEB, 1 μg/ml resiquimod (R848) (Invivo-
Gen)—a toll-like receptor 7 and 8 ligand, a potent acti-
vator of both monocytes and B cells—, 10 μ/ml CD3/28
beads (Gibco, Life Technologies) for 18 h or 100 ng/ml
phorbol myristate acetate (PMA, Sigma) and 1 μg/ml
ionomycin (iono, Sigma) for 6 h at 37 °C.
For mRNA analysis, cells were lysed with RLT Plus
buffer (Qiagen) and kept at −20 °C until further
extraction.ELISA
Measurement of IL-22 in the serum, cerebrospinal fluid
(CSF), or supernatant of stimulated PBMC was performed
with the Human IL-22 ELISA Ready-SET-Go (eBioscience)
according to manufacturer’s instructions and read with
Opsys MR (Dynex International) instrument.
Table 2 Study subjects for the assessment of IL-22 and IL-22 receptor in the brain










MS type Disease duration
(years)
Lausanne cohort
L-C1 F 60 Biopsy – Cerebellar softening – – –
L-C2 M 31 Biopsy – Epilepsy – – –
L-C3 F 51 Biopsy – Hematoma – – –
L-C4 M 43 Biopsy – Aneurysm – – –
L-C5 M 41 Biopsy – Hematoma – – –




L-C7 n/a n/a Biopsy – Glioblastoma – – –
L-C8 M 32 Biopsy – Cavernoma – – –
L-C9 F 53 Biopsy – Epilepsy – – –
L-C10 M 51 Biopsy – Malformation – – –
L-C11 M 39 Biopsy – Epilepsy – – –
Basel cohort






B-C2 M 64 Autopsy Occasional hypoxic neurons,
perineuronal oedema, stasis of
erythrocytes in vessels, many
leukocyte infiltrates
Cardiac failure 18 – –





B-C4 M 35 Autopsy – Carcinoma of the
tongue
22 – –
B-C5 M 64 Autopsy Occasional hypoxic nerve cells,
perineuronal oedema, fibrosis of the
meninges
Cardiac failure 18 – –
B-C6 F 84 Autopsy Old cortical microinfarcts and acute
global hypoxic changes. Senile







B-C7 F 60 Autopsy Brain with diffuse hypoxic changes Ovarian cancer 13 – –
B-MS1 M 40 Autopsy No lesion, few leukocyte infiltrates Respiratory failure,
sepsis, MS
10 SP-MS 9





B-MS3 F 34 Autopsy Lesions in GM and WM, leukocytes
around vessels
Pneumonia 12 SP-MS n/a
B-MS4 F 49 Autopsy Lesions in WM, leukocytes infiltrates Bronchopneumonia,
MS
7 SP-MS 21
B-MS5 M 44 Autopsy n/a Bronchopneumonia 16 SP-MS n/a
M male, F female, C control, MS multiple sclerosis, B Basel, L Lausanne, GM gray matter, n/a not available, SP secondary progressive, WM white matter
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home-made kit. “Maxisorp Immunoplates” 96-well
plates (Nunc) were coated with coating solution (15 mM
Na2CO3, 34.8 mM NaHCO3) mixed with goat anti-IL-
22BP antibody (AF1087, R&D Systems) diluted 1:500
and incubated overnight at 4 °C. The next day, blockingwas performed by filling 200 μl/well PBS containing 0.05
% Tween 20 and 1 % bovine serum albumin (BSA) (PBS/
T-1 % BSA) (Sigma) with 2 h incubation at 37 °C. After
three washes with wash buffer solution (BD Biosciences),
100-μl standard dilutions (1087-BP-025, R&D Systems)
and samples diluted with 50 μl PBS/T-1 % BSA were
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third day, plates were washed three times and 50 μl/well
of rabbit anti-IL-22BP (sc-134974, Santa Cruz Biotech-
nology) diluted 1:200 in PBS/T-1 % BSA were added and
1 h incubation at 37 °C was performed. Following three
washes, addition of 50 μl of mouse anti-rabbit biotinyl-
ated antibody (550346, BD Biosciences) diluted 1:3,000
in PBS/T-1 % BSA was performed and the plates were
incubated 1 h at 37 °C. After another round of three
washes, 50 μl/well of 1:200 streptavidin-HRP (DY998,
R&D Systems) in PBS/T-1 % BSA was added and incu-
bated at RT for 30 min. Finally, after six washing steps,
ELISA was revealed and developed with 100 μl/well
revelation buffer (DY999 R&D Systems) in a 20-min in-
cubation period at RT, protected from light. Reaction
was stopped with 50 μl/well 1 M H2SO4, and plates were
read at 450 nm with Opsys MR (Dynex International)
device. Detection limit was set at 0.5 ng/ml to fully guar-
antee specificity and reliability of positive samples, based
on data of the recombinant IL-22BP standard curve
(R&D Systems).
RNA extraction, reverse transcription and quantitative
PCR
The biological material was lysed with RLT Plus buffer
(Qiagen) and stored at −20 °C until RNA extraction. The
RNA isolation was performed with the RNeasy Plus
Mini kit (Qiagen). Up to 0.5-μg purified RNA (concen-
tration measured with a NanoDrop 2000, Thermo Scien-
tific) was taken for reverse transcription utilizing the
Quantitect Reverse Transcription kit (Qiagen). Quantita-
tive PCR was performed with the QuantiTect SYBR
green PCR mix (Qiagen) and QuantiTect primer assays
for 18S ribosomal RNA, IL-22BP set (Qiagen). Micro-
Amp Fast Optical 96-well reaction plate (Applied Biosys-
tems, Life Technologies) was run with a StepOnePlus
Real-Time PCR System (Applied Biosystems, Life Tech-
nologies). The relative expression of each sample was
calculated with the “2e(−ΔCt)” equation where the Ct is
defined as the cycle number at which the SYBR green
fluorescence crosses the threshold (arbitrary set and
fixed for all experiments performed) and the Δ is the dif-
ference between the Ct of the sample tested and the
housekeeping gene Ct. Melting curve analysis was per-
formed to ensure reaction specificity.
Immunohistochemistry
For immunohistochemistry staining, tissue sections were
treated with 0.6 % hydrogen peroxide in 80 % methanol
for 30 min to inactivate endogenous peroxidase and
blocked with blocking buffer (1 % normal donkey serum,
0.1 % Triton, 0.05 % Tween) for 1 h. The tissue sections
for myelin oligodendrocyte glycoprotein (MOG) were
then additionally defatted in 100 % methanol for 8 minat −20C°. Sections were incubated with following pri-
mary antibodies overnight at 4 °C: mouse anti-MOG
(clone Z12, kindly provided by R. Reynolds) to target
myelin, mouse anti-IL-22R1 (clone 305405, R&D Sys-
tems)/mouse IgG1 isotype control (clone 11711, R&D
Systems), rabbit anti-glial fibrillary acidic protein (GFAP)
(AB5804, Millipore; Z0334, DakoCytomation) to label
astrocytes, and rabbit anti-Caveolin-1 (Cav-1) (N-20,
Santa Cruz Biotechnology) for endothelia staining/rabbit
IgG isotype control (AB-105-C, R&D Systems; 12–370,
Millipore). Secondary biotinylated antibodies (Vector
Laboratories) were applied for 1 h at room temperature,
together with 4′,6-diamidino-2-phenylindole (DAPI,
Invitrogen Life Technologies) counterstaining, followed
by avidin-biotin complex reagent (Vector Labs) for 30
min. Color reaction was performed with 3-amino-9-
ethylcarbazole. Cells were stained in hematoxylin for 5
min and rinsed afterwards under running tap water.
Image acquisition was performed with a Zeiss Axiovision
(Carl Zeiss Microscopy) microscope, and picture analysis
was performed with Axiovision software (version
V4.8.1.0, Carl Zeiss Microscopy).
Laser scanning confocal microscopy
Immunostainings were performed with the following
primary antibodies: goat anti-IL-22 (AF782, R&D Sys-
tems)/goat IgG (AB-108-C, R&D Systems), mouse anti-
IL-22R1 (clone 305405, R&D Systems)/mouse IgG1
(clone 11711, R&D Systems), rabbit anti-IL-10R2 (sc-
69580, Santa Cruz Biotechnology), rabbit anti-GFAP
(AB5804, Millipore; Z0334, DakoCytomation), mouse
anti-GFAP-Cy3 (for HA only, clone G-A-5, Sigma),
rabbit anti-Caveolin-1 (N-20, Santa Cruz Biotechnol-
ogy)/rabbit IgG (AB-105-C, R&D Systems; 12–370,
Millipore), sheep anti-von Willebrand factor (VWF)
(GTX74137, GeneTex) for vessel labeling, and chicken
anti-microtubule-associated protein (MAP)-2 (ab5392,
Abcam) to target neurons/chicken IgG (GTX35001,
GeneTex) and with the following secondary antibodies:
donkey anti-goat IgG AF488, donkey anti-mouse IgG
AF546 and AF647, goat anti-rabbit IgG AF488, donkey
anti-rabbit IgG AF647, goat anti-chicken IgG AF647,
goat anti-sheep AF647 (Invitrogen) and, finally, donkey
anti-rabbit IgG AF488 (Jackson ImmunoResearch) and
donkey anti-rabbit IgG CSL467 (Santa Cruz Biotechnol-
ogy). To reduce autofluorescence, tissue sections of the
Basel cohort were incubated in cupric sulfate in ammo-
nium buffer (10 mM CuSO4, 50 mM CH3COONH3, pH
5.0) for 30 min before secondary antibody staining. Nu-
clei staining was done with DAPI (Invitrogen Life Tech-
nologies). Slices were mounted with Vectashield (Vector
Laboratories). Image acquisition was done with a Zeiss
LSM 710 Quasar (Carl Zeiss Microscopy) confocal, and
picture analysis was performed with Zeiss ZEN 2009
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Institutes of Health), and Axiovision softwares (version
V4.8.1.0, Carl Zeiss Microscopy). Images were taken,
and post-acquisition processing (brightness and con-
trast) was done the same way for specific antibodies and
their isotype controls.
Proliferation and cell death/apoptosis assays
For functional experiments, cells were cultured at low
passage (three to six passages) in complete astrocyte
medium, prior to transfer in 24-well plates (Costar) at
20,000 cells/well in RPMI only medium, 300 μl/well, on
day −1. On day 0 and then every other day over a 9-day
period, HA were treated with six different conditions:
astrocyte medium without FCS as reference medium;
RPMI only (referred as “untreated” or negative control) as
standard minimal medium to provide only essential nutri-
ent to the cells; IL-22 at 50 ng/ml (R&D Systems); tumor
necrosis factor (TNF)α at 10 ng/ml (R&D Systems); TNFα
and IL-22 co-treatment; and finally, 100 nM staurosporine
(STS, Sigma) as positive control to induce apoptosis and
cell death. TNFα was chosen as a pro-inflammatory cyto-
kine considering its paramount role in MS [38].
To assess for cell proliferation, carboxyfluorescein suc-
cinimidyl ester (CFSE, Biolegend) staining was done at
the beginning of the kinetic (day −1), such as already
performed in the lab [39], whereas to assess for cell
death and apoptosis, staining with 7-aminoactinomycin
D (7-AAD, BD Biosciences) and Annexin V AF647 (Invi-
trogen Life Technologies) in Annexin-binding buffer
(Invitrogen Life Technologies), respectively, were per-
formed at day 1, 2, 3, 4, 5, 7, and 9, according to manu-
facturer’s instructions. Annexin V marker analysis was
performed on 7-AAD− pregated cells. Samples were run
with an LSRII flow cytometer (BD Biosciences) and were
analyzed with FlowJo software (version 9.1.11, Treestar).
Statistical analysis
Statistical analyses were performed with GraphPad Prism
software (version 6.04, GraphPad Software). The differ-
ences among groups (three or more) were first tested
using Kruskal-Wallis test for multiple non-normally dis-
tributed variables. Unpaired non-parametric two-tailed
Mann–Whitney was used to test groups two-by-two. A
P value < 0.05 was considered significant.
Results
Increased IL-22 in active MS patients
First, using ELISA, we found that there was a strong
trend (p = 0.07) for an increase of IL-22 protein in the
serum of 63 MS patients as compared to 13 HC (Fig. 1a).
Interestingly, the level of IL-22 in the serum of MS pa-
tients with active disease was higher than in the serum
of inactive (p = 0.017) and progressive (p = 0.015) MSpatients and, especially, of HC (p = 0.003) (Fig. 1b). IL-
22 was not detectable in the CSF of patients with active
MS (Fig. 1c). Of note, no lumbar puncture was per-
formed in the other categories of study patients.
Next, we found that the supernatant of SEB-stimulated
PBMC of 74 MS patients secreted a higher amount of
IL-22 than of 32 HC (p = 0.0436, Fig. 1d), a finding
which was ascribable to the active category of MS pa-
tients (active versus HC: p = 0.0048, active versus in-
active: p = 0.0216, Fig. 1e). Then, we investigated which
leukocyte subtypes secreted IL-22. We found that CD4+
T cells accounted for most of the production of IL-22;
nevertheless, and as already reported, monocytes, B cells,
CD8+ T cells, and natural killer (NK) cells were also able
to produce and secrete significant amount of IL-22
(Additional file 1: Figure S1) [40]. Of note, unstimulated
PBMC released a low, but not null, level of IL-22, con-
sistent with previous reports [41]. Therefore, we tested
several polyclonal stimulations (SEB, R848, PMA/iono-
mycin, and CD3/CD28 beads), and all showed similar ef-
ficacy, except for R848 which was induced much less IL-
22 secretion from CD4+ T cells than other stimulants
(Additional file 1: Figure S1).
To further examine the putative implication of IL-22
in MS, we looked at its soluble antagonist, i.e., IL-22BP.
Indeed, IL-22BP gene polymorphism has been recently
associated with MS [32]. Looking first at the protein
level, we did not find a difference in terms of IL-22BP
protein in the sera of 63 MS patients versus 13 healthy
controls (HC); however, there was a trend (p = 0.14) to-
wards an increased secretion of IL-22BP in MS patients
as compared to HC (Fig. 1f ). Those 76 study subjects
and patients were the very same who were tested for the
content of IL-22 in the serum (see above). Some MS pa-
tients harbored high levels of soluble IL-22BP, reaching
levels of 10 ng/ml and more (Fig. 1f–g); however, there
was no difference between the categories of MS patients
(Fig. 1g). Interestingly, IL-22BP was detected in the CSF
of 13/15 active MS patients who had a lumbar puncture
at the same time as this assay (Fig. 1h).
Then, we found that among different sorted subpopu-
lations of blood immune cells, CD14+ monocytes and,
especially, in vitro differentiated moDCs contained the
highest levels of mRNA coding for IL-22BP (Additional
file 2: Figure S2), confirming previous literature data
[31, 35, 42, 43]. We found an increased expression of IL-
22BP mRNA in the monocytes of 51 patients as com-
pared to 30 HC (p = 0.016; Fig. 1i) and in the moDCs of
a subset of 15 MS patients as compared to 10 HC
(p = 0.016; Fig. 1k). Interestingly, although there was no
difference between the categories as a whole (p = 0.108
with the Kruskal-Wallis test), the higher expression of
IL-22BP mRNA in the monocytes of MS patients
seemed to be mostly accountable to the category of
Fig. 1 (See legend on next page.)
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Fig. 1 IL-22BP and IL-22 are increased in MS patients as compared to healthy controls. The IL-22 and IL-22BP expressions were assessed by ELISA
(a–h) and qPCR (i–k) in the serum (a, b and f, g), CSF (c, h), isolated monocytes (i, j), and moDCs (k) and supernatant of SEB-stimulated PBMC
for 18 h (d, e) isolated from MS patients and healthy controls. Each dot represents a patient. The bars represent the median. Dashed red lines
represent the detection limit. Active: clinically active MS patients, inactive: clinically inactive MS patients, progressive: primary and secondary
progressive MS patients. Differences among the four groups were significant with Kruskal-Wallis test (b, e). Unpaired non-parametric Mann–Whitney
test was used to compare groups two-by-two. *P < 0.05, **P < 0.01
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Fig. 1j).
IL-22 and IL-22R1 expression in the human brain
The fact that IL-22 and its soluble antagonist receptor,
IL-22BP, are differentially expressed in MS patients as
compared to HC suggests that this cytokine may be in-
volved in the immunopathogenesis of MS. For this rea-
son, we looked for putative target cells of IL-22 in the
CNS. This cytokine is recognized through the IL-22 het-
erodimeric receptor composed of IL-10R2 and IL-22R1
subunits [44]. Of note, IL-10R2 can also bind IL-10,
IL-26, IL-28(α/β), and IL-29, whereas IL-22R1 binds also
IL-20 and IL-24 [30, 45], but only IL-22 is recognized
by these two subunits together [45]. IL-10R2 has been
previously shown to be expressed ubiquitously among tis-
sues from hematopoietic and nonhematopoietic origins,
whereas IL-22R1 expression was absent on hematopoietic
cells [14, 41].
Here, to explore whether human brain CNS cells ex-
press the IL-22 receptor and whether IL-22 is present in
the brain, we analyzed brain tissue sections from five
MS cases and 18 non-MS controls. Using immunohisto-
chemistry peroxidase staining, we aimed at detecting IL-
22 and IL-22R1 on adjacent tissue sections with pictures
taken at the exact same area for all samples (Fig. 2). We
were able to detect IL-22 and IL-22R1 in the GM and
the WM of both control subjects (Fig. 2a) and MS pa-
tients, either in areas deprived of lesions (Fig. 2b, c) or
at the vicinity of plaques (Fig. 2d). Isotype controls
showed that there was no unspecific staining neither of
the primary nor of the secondary antibodies used in
Fig. 2 (Additional file 3: Figure S3). Of note, MS plaques
were identified by MOG and HE staining (example is
shown in Fig. 2d). The expression of the cytokine and its
receptor was clearly stronger in MS than control tissue
(Fig. 2b–d compared to Fig. 2a). Interestingly, the
morphology of the IL-22- and IL-22R1-positive cells
clearly looked alike GFAP-positive astrocytes (Fig. 2c,
arrow, first to third row), suggesting that the receptor
and its cytokine were present on the same cells, for ex-
ample see the two upper panels of Fig. 2c. The IL-22-
and IL-22R1 expressing cells were often found in the
vicinity of blood vessels. Since IL-22R1 was identified to
be expressed by endothelial cells in MS [22], we stained
for Caveolin-1. However, we found that the staining ofIL-22 and its receptor reflected more the staining of
GFAP than the one of Caveolin-1 (Fig. 2c, d in particu-
lar). Caveolin-1 delineates very nicely in blood vessels,
whereas IL-22 and IL-22R1 are localized on fine pro-
cesses around blood vessels and on cell bodies of stellate
cells in proximity of blood vessels. Moreover, in MS
lesions where strong astrogliosis occurs, IL-22 and IL-
22R1 expressions was also enhanced (Fig. 2d).
Next, using immunofluorescent confocal microscopy,
we wanted to determine whether IL-22 and IL-22 recep-
tor indeed colocalize on the same cells. We also wanted
to ascertain their expression on astrocytes as indicated
by light microscopy (Fig. 2). We found that IL-22 colo-
calized with its receptor in the brain tissues of control
subjects (Fig. 3a–d) as well as in the brain tissues of MS
patients (Fig. 4). In the brain of control subjects, the IL-
22/IL-22R1 colocalization seemed to be slightly more
expressed in the GM than in the WM (Fig. 3a, b),
whereas in MS, it was clearly stronger in the plaques, ei-
ther in the WM (Fig. 4a, b) or the subpial GM (Fig. 4c,
d), than in the normal appearing white matter (NAWM)
(Fig. 4a, b). We were also able to confirm that the IL-22/
IL-22R1 couple was expressed on astrocytes in the brain
of control subjects (Fig. 3a, c) as well as of MS patients
(Fig. 4a, c). By contrast, co-staining of the IL-22/IL-22R1
with Cav-1 was rarely detected (less than 1 % of Cav-1+
structures were also positive for IL-22/IL-22R1) (Fig. 3b).
By analyzing adjacent slices of pictures taken at the very
same location, we noticed strong IL-22R1 expression in
white matter plaques (Fig. 4a, b) as well as in subpial le-
sions in gray matter (Fig. 4c, d).
To ascertain the specificity of the antibodies used for
immunofluorescent confocal microscopy and to rule out
autofluorescence, we performed isotype stainings, using
the exact same protocol, acquisition parameters, and post-
processing analysis methodology as for specific antibodies
(Additional file 4: Figure S4 and Additional file 5: Figure
S5). Of note, the pictures of the isotype controls were
taken at the very same location in the tissue slices as the
pictures of the specific antibodies, except for Additional
file 4: Figure S4c, which was not immediately adjacent to
Fig. 3c, d. Otherwise, tissue pictured in Additional file 4:
Figure S4a, b was immediately adjacent to the one repre-
sented in Fig. 3a, b; the same was true for Additional file 5:
Figure S5a with Fig. 4a, b and Additional file 5: Figure S5b
with Fig. 4c, d.
Fig. 2 IL-22 and IL-22R1 are expressed in human brain. IL-22, IL-22R1, GFAP, and Caveolin-1 immunohistochemistry peroxidase stainings of brain
tissue sections of control (a) and MS (b–d) patients. MOG and HE stainings were used to detect MS demyelinating plaques (d). All four pictures
belonging to one column (a, b, c, or d) were always immediately adjacent to each other. Pictures a, b, and c were taken at areas at the border
between GM and NAWM, whereas pictures in d were taken from the same location at the edge between NAWM and a plaque. Inserts in columns
a and b represent a threefold magnification of the selected area. Arrow: astrocyte-like pattern. a study patient B-C2, b and d study patient B-MS3,
c study patient B-MS5 (Table 2). Scale bar, 50 μm (a, b: ×20, c, d ×40). GM: gray matter, NAWM: normal appearing white matter, WM: white matter.
Representative pictures obtained from the observations of seven control and five MS autopsy samples
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Fig. 3 Specific expression of IL-22 and its receptor, IL-22R1, by astrocytes in the brains of control patients without MS and suffering from other
neurological diseases. Laser scanning confocal microscopy observations were performed in brain tissue autopsies (Basel cohort). Brain autopsy
labeled for IL-22 (first panel, green), IL-22R1 (second panel, red), and Caveolin-1 or GFAP (third panel, blue). Merged images are depicted as composite
images in the lower panel (colocalization of IL-22R1 and GFAP appears in yellow and triple colocalization of IL-22, IL-22R1, and GFAP in white). Inserts
are a ×10 zoom of the selected area (a, b, lowest panels). Images a and b were taken on autopsied brain tissue from control patient B-C6 and c and d
from control patient B-C1 (Table 2). Arrows in a point at astrocytes, and stars in b at blood vessels. Bars, 50 μm. GM: gray matter, WM: white matter.
Representative pictures obtained from the observations of seven control autopsy samples
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trol patient L-C5 confirmed that there was a very strong
colocalization of IL-22R1 with GFAP (Additional file 6:
Figure S6a) but not with Cav-1 (Additional file 6: Figure
S6b, c) or with MAP-2 (Additional file 6: Figure S6c).
Staining with anti-VWF, an alternative blood vessel
marker, led to the same results as with anti-Cav-1, i.e.,
no colocalization with IL-22R1 (Additional file 7: Figure
S7). Interestingly, IL-22R1 expression was particularly
high in the close vicinity of blood vessels, lining themup. However, we could show that this proximity was not
due to endothelial expression of IL-22R1 (Additional
file 6: Figure S6b) but was rather attributable to expres-
sion by astrocytic feet. Of note, to ascertain that the de-
tection of IL-22R1 used so far indeed indicated the
expression of the whole IL-22 receptor, we assessed the
expression of the other subunit of the IL-22 receptor,
i.e., IL-10R2, and found that, indeed, IL10R2 colocalized
with IL-22R1, clearly establishing that the heterodimeric
IL-22 receptor complex is fully expressed in the CNS
Fig. 4 Strong expression of IL-22 and its receptor, IL-22R1, in the plaques of MS brains. Immunofluorescence of human brain tissue sections
stained for IL-22 (green), IL-22R1 (red), and Cav-1 or GFAP (blue) in MS brain tissue autopsies. Images were taken from patient B-MS3 patient
(Table 2) in a plaque located in the subcortical WM (a, b) and in a plaque located in the subpial GM (c, d). The lowest panels depict a ×5
magnification of the white squares displayed in the above panels. Arrow: astrocytes, star: blood vessels. Arrowheads point at triple IL-22/IL-22R1/
GFAP colocalization (a, c). Bars, 50 μm. NAWM: normal appearing white matter. Representative pictures obtained from the observations of five MS
autopsy samples
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experiments establishes that the IL-22 receptor is
expressed in the human brain, mostly on astrocytes, and
that IL-22 colocalize with its receptor. We also demon-
strate that even if the IL-22/IL-22R1 couple is present in
the brain of control patients with other neurological dis-
ease than MS, it nevertheless predominates in the brain
of MS patients, in particular in the plaques.
IL-22 increased the survival of astrocytes
Having shown that the IL-22 receptor was expressed in
the human brain, predominantly by astrocytes, we decided
to investigate the role of IL-22 on astrocytes. To this end,
we selected human primary astrocytes. The purity of those
primary astrocytes, as assessed by GFAP staining on flow
cytometry, was close to 80 % (Additional file 8: Figure S8).
Such as shown by flow cytometry (Fig. 5a) and by im-
munofluorescence (Fig. 5b–d), these astrocytes expressed
both subunits of the IL-22 receptor, confirming that IL-22
could bind to these cells.
In order to determine whether IL-22 has a protective
or deleterious effect on astrocytes, we studied its impact
in terms of cell death, such as measured by 7-AAD, a
marker of cell viability.
We found that IL-22 protected human astrocyte from
cell death. Indeed, nutriment-deprived astrocytes that
had been treated with IL-22 (plain blue line) exhibited a
significant higher survival than astrocytes cultured in the
same conditions but without IL-22 (dashed blue line)
(Fig. 6a, c). Even if the improved survival of astrocytes
attributable to IL-22 was relatively mild (increase of sur-
vival 2.4 % on day 2, 7 % on day 3, and 4.2 % on day 5),
it was significant and occurred during a time of the cul-
ture (day 2, 3, and 5), which corresponded to a nadir in
terms of astrocyte survival (Fig. 6c, blue lines).
Then, we assessed whether the protective function of
IL-22 on astrocytes was maintained in a still more hos-
tile environment, i.e., under inflammatory conditions.
Therefore, we compared TNFα-treated astrocytes with
or without adding IL-22. We found that whereas there
was a steady and constant cell death of the TNFα-
treated astrocytes population which had not received IL-
22 (dashed red line) (Fig. 6b, c), there was a much better
survival of astrocytes co-treated with TNFα and IL-22
(plain red line) from day 7 (Δ = 8.9 %) to day 9 (Δ =
20.6 %) (Fig. 6b, c). Regarding TNFα- versus IL-22- and
TNFα-treated human astrocyte conditions, TNFα-
treated cells showed steady shrinkage of surviving cell
number till the end of the kinetic (Fig. 6c). Addition of
IL-22 to the TNFα-treated cells drastically ameliorated
cell survival from day 7 on, as reflected by the decreased
frequency of 7-AAD-positive coupled with a rise of 7-
AAD-negative cell frequency, i.e., more alive astrocytes.In an attempt to determine if an anti-apoptotic mech-
anism may account for the protective effect of IL-22, we
assessed whether, among 7-AAD-negative living cells,
there were cells in an early stage of apoptosis, such as
revealed by Annexin V staining. Gating on live cells only
(7-AAD-negative), we found that the mean fluorescence
intensity (MFI) of Annexin V was significantly less in-
tense in IL-22-treated cells than their untreated counter-
parts on the first day of culture (27.1 % MFI difference),
showing that the former was less apoptotic than the
latter (Fig. 6d). Furthermore, we found that IL-22 treat-
ment significantly attenuated the pro-apoptotic effect
of TNFα on day 9 of the assay (22.8 % MFI decrease,
Fig. 6d).
Finally, some authors have shown that IL-22 promotes
proliferation of epithelial cells [19]. Thus, we examined
whether the pro-survival effect of IL-22 on astrocytes
could be ascribed to this property of IL-22. However, we
did not find such an effect of IL-22 (data not shown).
Discussion
So far, IL-22 has been barely studied in the context of
MS. Possible reasons may include the unchanged course
of EAE in mice deficient for IL-22 as compared to wild-
type mice [46] and also the fact that this cytokine does
not target immune cells [14, 21, 41]. Yet, there are some
elements suggesting that this cytokine may be involved in
the immunopathogenesis of MS. Indeed, a polymorphism
of the gene coding for interleukin-22 binding protein be-
tween MS patients and controls has been described re-
cently [32]. Interestingly, in EAE, IL-22BP knock-out mice
have a decreased neuroinflammatory profile and an overall
less severe disease course as compared to wild-type litter-
mates, strongly suggesting that IL-22 attenuates disease
severity [35].
We found that the level of IL-22 was higher in the
serum of MS patients than HC (Fig. 1a). In fact, this in-
crease was entirely attributable to MS patients with ac-
tive disease (Fig. 1b). This increase of serum IL-22
seems to be attributable to an increased secretion of this
cytokine by PBMC (Fig. 1d, e), in particular CD4+ T cells
(Additional file 1: Figure S1) [41]. Similarly to us, others
recently found that CD4+ T cells, and more specifically
Th17 and Th22 cells, of MS and neuromyelitis optica
(NMO) patients secreted more IL-22 than those of HC
[47, 48]. Our results are supported by findings in Lewis
rats where the expression of IL-22 is increased during
the acute phase of EAE and decreased in its recovery
phase, while IL-10 and IL-17 levels remain unchanged.
These variations suggest that there is a tight correlation
between this cytokine and the disease course [49]. Thus,
in an attempt to understand the regulation of IL-22, we
examined IL-22BP, the soluble antagonist receptor of IL-
22. Contrasting with IL-22, we saw no difference between
Fig. 5 Colocalization of both subunits of IL-22 receptor on primary astrocytes. a Flow cytometry experiments show the expression of both
subunits of the IL-22 receptor, IL-10R2, and IL-22R1 (in red), on human primary astrocytes (HA) as compared to their isotype control counterparts
(in black). b–d By immunofluorescent confocal microscopy, there is a colocalization of GFAP (green) with IL-10R2 (red) (b) and with IL-22R1 (red)
(c) as well as of IL-10R2 (green) with IL-22R1 (red) (d). The colocalization appears is depicted in yellow (arrows, MERGE). DAPI is represented in blue
and not included in MERGE overlay. Bars, 50 μm
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found that mRNA coding for IL-22BP was mainly pro-
duced by monocytes and moDCs (Additional file 2: Figure
S2), corroborating what has recently been described in
mice and humans [35, 43]. We then found that the levelof IL-22BP coding mRNA was higher in the monocytes
and moDCs of MS patients than HC (Fig. 1i, k). Neverthe-
less, contrasting again with IL-22, this increase was not
clearly ascribable to MS patients with active disease, even
if there was a trend (Fig. 1j). Altogether, these data suggest
Fig. 6 Enhanced survival of IL-22-treated primary astrocytes in insulting conditions. Primary astrocyte cells (HA) were cultured in 24-well plates
starting at day −1 and were treated every second day starting at day 0 with astrocyte medium (AM)—representing the optimal culture medium
for astrocytes—or with RPMI (poor medium, hereafter referred to as untreated), with or without addition of the following: IL-22 alone, TNFα alone,
IL-22 and TNFα together, or still staurosporine (STS) alone, the latter representing a potent inducer of apoptosis. Cells were stained with 7-AAD
and Annexin V and analyzed by flow cytometry to assess their survival and apoptotic status. Histograms represent 7-AAD profile of untreated
versus IL-22 (a) and of TNFα versus IL-22 + TNFα (b). Survival profile analysis was performed by flow cytometry by following the frequency of
living cells (i.e., 7-AAD-negative cells, Fig. 6 c) and, among those that were not dead (7-AAD-negative cells), by following the proportion of those
surviving cells but which underwent apoptosis (d). Each dot represents the median of six replicates, except for AM and STS conditions (three
replicates). Orange arrows indicate treatment renewal. Considering STS treatment, 7-AAD kinetic was stopped after 4 days as all recovered cells
were dead at this time point.*comparison of IL-22-treated versus untreated cells; †comparison of TNFα- versus TNFα + IL-22-treated cells. The
vertical bars determine the 75th percentile of the median. Significance was calculated with unpaired non-parametric Mann–Whitney test.
* or †P < 0.05, ** or ††P < 0.01
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the case for instance for the control of IL-1β by IL-1RA
[50]. Yet, during a relapse, IL-22 seems to “overrule” this
control, such as revealed by the significant increase of IL-
22 in the serum of those patients.
Somewhat contrasting with the data in peripheral
blood, we found that, in the CSF of active MS patients,
IL-22BP (Fig. 1h), but not IL-22 (Fig. 1c), was detectable.
The absence of IL-22 in the CSF of active MS patients
(Fig. 1c) may simply indicate that IL-22 plays no role at
the CNS level. However, we do not think that this obser-
vation should lead to such conclusion. First, it is wellestablished that the absence of a cytokine in the CSF
does not preclude a paramount role in CNS inflamma-
tion, such as reflected, for instance, by IL-6 [32, 51]. Sec-
ond, and more important, since IL-22BP was present in
the CSF of active MS patients (Fig. 1h), it is tempting to
hypothesize that it is in reaction to its ligand, i.e., IL-22.
Third, confirming the results of others [14], we were not
able to detect IL-22R1 on hematopoietic cells (data not
shown), further pointing to the rationale to search for
other target cells, in this case, the brain.
Thus, we examined whether brain cells did express IL-
22 receptor. Whereas IL-10R2 is more or less ubiquitous
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stricted. Therefore, having shown that both subunits of
IL-22 receptor colocalized on astrocytes (Additional file 6:
Figure S6d), we thereafter focused on the more restrictive
subunit IL-22R1. A major finding was the expression of
IL-22R1 on astrocytes of both control and MS patients
but clearly predominating in the latter. In particular, this
expression was high in MS plaques or adjacent to blood
vessels, pointing to a wide expression in perivascular
astrocyte end feet (Fig. 4). Such as Kebir et al., we ob-
served colocalization of IL-22R1+ and caveolin-1+, indicat-
ing an expression of this receptor by endothelial cells [22];
but in our hands, this expression was restricted to the
brain of non-MS patients and in the NAWM of one MS
patient and was of limited extent. We could also rule out
a constitutive expression of IL-22R1 by neurons since we
never observed MAP-2+ and IL-22R1+ colocalization
(Additional file 6: Figure S6c).
The IL-22 cytokine was shown to be expressed in the
brain and spinal cord of mice [52, 53]. Having demon-
strated that human astrocytes expressed high levels of
the IL-22 receptor, we subsequently looked for IL-22
presence in the CNS. We found that this cytokine was
indeed present and that it colocalized with IL-22 recep-
tor on astrocytes, further suggesting that IL-22 targets
astrocytes. However, whether the detected IL-22 was of
lymphocytic origin or whether it was produced by resi-
dent cells of the CNS, for instance astrocytes themselves
in an autocrine fashion, remains to be determined. The
fact that IL-22 was not detected in the CSF somewhat
argues for a production by CNS resident cells rather
than a secretion by T cells. Nevertheless, one should
not forget that IL-22 in the CSF may also be trapped by
IL-22BP, since, in our hands, the latter was detected in
the CSF.
Astrocytes are crucial to maintain CNS homeostasis and
are now recognized to play a role in the pathogenesis of
autoimmune demyelinating diseases. In NMO, a CNS dis-
ease sharing many features with MS, astrocytes play a
central role as they are the cells expressing aquaporin-4
(AQP4), a water channel embodying the antigen against
which the autoimmunity of the NMO antibodies is di-
rected [54, 55]. In MS, astrocytes have been increasingly
recognized as being an important component of the
pathogenesis of the disease [56, 57]. KIR-4.1, which was
recently found to be a possible target of auto-antibodies in
human MS, is also expressed by oligodendrocytes and as-
trocytes [58]. To explore what could be the effect of IL-22
on astrocytes, we resorted to primary human astrocytes.
We could confirm that these cells had astrocyte-
characteristics and harbored both IL-22 receptor subunits
(Fig. 5). We found that IL-22-treated astrocytes exhibited
an increased survival as compared to untreated ones, and,
interestingly, this effect was maintained in inflammatoryconditions since IL-22 mitigated the effect of TNFα. This
effect was mediated, at least in part, by a decrease of apop-
tosis. Supporting these findings, previous studies have
shown that IL-22-treated rat pheochromocytoma cells
exhibit a modest increased survival in serum-deprived
conditions [59]. Some authors have found that IL-22 in-
creased the proliferative function of keratinocytes [19, 60]
or colonic epithelial cells [42]. While we could reproduce
these data on HaCaT keratinocyte cell line, we did not ob-
serve any proliferative effect of IL-22 on primary human
astrocytes (data not shown), further pointing to a pro-
survival effect of IL-22 on existing astrocytes. Further
studies investigating by which mechanism(s) IL-22 modu-
lates astrocyte survival are warranted to better understand
the role of this cytokine on its newly defined CNS target.
Conclusions
In conclusion, we have shown (i) that MS patients in re-
lapse harbor significantly higher serum levels of IL-22, (ii)
that astrocytes express the IL-22 receptor, (iii) that there is
a colocalization of IL-22 with astrocytes, and (iv) that IL-
22 has pro-survival properties on primary human astro-
cytes. Astrocytes can play a dual role when challenged,
depending on the nature of the insult, harboring either a
beneficial or a detrimental phenotype [57]. Thus, having
shown that IL-22 is a player in the immunopathogenesis
of MS, we will now examine whether the net effect of IL-
22 on astrocytes is pro- or anti-inflammatory.
Additional files
Additional file 1: Figure S1. Different leukocyte subtypes are able to
produce and release IL-22 upon stimulation. Total PBMC were isolated
and MACS-sorted into monocytes (CD14+), B cells (CD19+), CD4+ T cells,
CD8+ T cells, and NK cells (CD56+). Cells were either treated with SEB,
R848, or CD3/CD28 beads (CD3/28) for 18 h, PMA/ionomycin (PMA/iono)
for 6 h, or left to rest for 18 h (unstim). Upon stimulation, all leukocytes
were able to secrete significant amount of IL-22. Nevertheless, CD4+ T
cells represented the major IL-22 source. Except for R848, all polyclonal
stimulations induced similar level of secreted IL-22 in each respective cell
subpopulation. Boxes represent the median, and bars the 75th percentile.
n = 5 study subjects.
Additional file 2: Figure S2. Monocytes and moDCs are the main
IL-22BP-expressing cells. Total PBMC were isolated and MACS-sorted into
monocytes (CD14+), B cells (CD19+), CD4+ T cells, CD8+ T cells, NK cells
(CD56+), and moDCs. Cells were either directly processed or treated for
6 h with PMA/ionomycin (PMA/iono) or stimulated for 18 h with SEB after
sorting. Expression level is relative to 18S ribosomal RNA housekeeping
gene.
Additional file 3: Figure S3. Peroxidase stainings are specific for IL-22,
IL-22R1, GFAP, and Caveolin-1 in autoptic brain tissue from control and
MS subjects. Immunohistochemistry peroxidase stainings of isotype
controls of goat anti-IL-22, mouse anti-IL-22R1, rabbit anti-GFAP, and
rabbit anti-Cav-1 antibodies. Pictures of A, B, C, and D have been acquired
at the exact same location as for specific antibodies and mirror exactly
panels A, B, C, and D, respectively of Fig. 2. Protocol and images were
processed exactly the same way for specific antibodies as for isotype controls.
Background is negative for goat and mouse isotype controls (respectively
IL-22 and IL-22R1 in Fig. 2). Background for the rabbit isotype control was
somehow higher, especially in blood vessels, but remained unspecific and
Perriard et al. Journal of Neuroinflammation  (2015) 12:119 Page 16 of 18thus did not compromise GFAP and Cavolin-1 specificity. A: study patient
B-C2, B and D: study patient B-MS3, C: study patient B-MS5 (Table 2). Scale
bar, 50 μm (A–B, ×20; C–D, ×40). GM: gray matter, NAWM: normal appearing
white matter, WM: white matter. Representative pictures obtained from the
observations of seven control and five MS autopsy samples.
Additional file 4: Figure S4. Immunofluorescence stainings are specific
for IL-22, IL-22R1, GFAP and Caveolin-1 in autoptic brain tissue from
control patients. Immunofluorescence staining of isotype controls of
goat anti-IL-22, mouse anti-IL-22R1, rabbit anti-GFAP and rabbit anti-Cav-1
antibodies. Panel A for A, B for B, and C for C and D, respectively, are
duplicates of images of Fig. 3 representing the same tissue location in the
brain. Few unspecific background/autofluorescence could be observed,
likely due to tissue quality (brain autopsies). The settings of isotype control
experiments were exactly the same as for specific antibodies experiments
(acquisition parameters and post-processing analyses). Images from panel
A and B were taken from B–C6 and C from B–C1 control patient autopsy
brain tissues, as for Fig. 3 (Table 2). Bars, 50 μm. GM: gray matter, WM: white
matter. Representative pictures obtained from the observations of seven
control MS autopsy samples.
Additional file 5: Figure S5. Immunofluorescence stainings are specific
for IL-22, IL-22R1, GFAP and Caveolin-1 in autoptic brain tissue from MS
patients. Immunofluorescence staining of isotype controls of goat anti-IL-
22, mouse anti-IL-22R1, rabbit anti-GFAP, and rabbit anti-Cav-1 antibodies.
Panel A for A and B, and B for C and D, respectively, mirror exactly images
in Fig. 4, being from the exact same location and processed identically
(same acquisition parameters and post-processing analyses). Thin unspecific
autofluorescent area in 488 and 564 nm could be observed. Pictures were
taken in patient B-MS3 brain section, again, as for Fig. 4 (Table 2). Bars, 50
μm. GM: gray matter, NAWM: normal appearing white matter, WM: white
matter. Representative pictures obtained from the observations of five MS
autopsy samples.
Additional file 6: Figure S6. Colocalization of GFAP and IL-10R2, but
not Cav-1 and MAP-2 with IL-22R1 in the brain. Laser scanning confocal
microscopy of brain biopsies labeled for IL-22R1 (red) in association
with: A) the astrocytic marker, GFAP (green), B) the caveolin-1 endothelial
marker (green), C) the caveolin-1 endothelial marker (white) and the
neuronal marker, MAP-2 (green), and D) the IL-10R1 subunit receptor
marker (green). DAPI staining (blue) is represented in inserts on the upper
left side. Images were taken on biopsied brain tissue from control patient
L-C5 (A to C) and L-C7 (D) (Table 2). Bar, 50 μm. Representative pictures
obtained from the observations of 11 control biopsy samples.
Additional file 7: Figure S7. There is a high degree of colocalization
between von Willebrand factor and Caveolin-1, but not between IL-22R1
and any of these two endothelial cell markers in the human brain.
Immunofluorescence confocal microscopy images of VWF (blue), IL-22R1
(red), and Cav-1 (green) of two slides, taken at different parts of the brain,
of L-C5 study subject (Table 2) are depicted (A and B). Counterstaining
was performed with DAPI. Bars, 50 μm.
Additional file 8: Figure S8. Large majority of GFAP-positive cells in
HA primary astrocytes. Flow cytometry histogram depicting GFAP stained
HA primary astrocytes (the bar indicates GFAP-positive cells, in percent).
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RR-MS: relapsing remitting multiple sclerosis; RT: room temperature;SEB: staphylococcal enterotoxin B; SLE: systemic lupus erythomatosus;
SP-MS: secondary progressive multiple sclerosis; Th cell: T helper cell;
TNF: tumor necrosis factor; VWF: von Willebrand factor; WM: white matter.
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